Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
In September 2025, the WHO added several GLP-1 drugs, including semaglutide and tirzepatide, to its Model List of Essential Medicines to improve global access to therapies used for diabetes and obesity-related conditions
Tirzepatide is a GLP-1 receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that works on your body's appetite and blood sugar systemsit does not transfer into plasma in ways that harm recipients
Common side effects include gastrointestinal issues, which typically decrease over time
Many users experience nausea, vomiting, diarrhea, and abdominal pain, especially when starting the treatment
In rare instances where standard stopper colours are unavailable, an alternative colour is used the SwissChems support team can confirm identification if required
